Cat. No：GM-C25349
Product：H_BCMA Reporter Cell Line
Cat. No：GM-C25349
Product：H_BCMA Reporter Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+0.75 μg/mL Puromycin+3.5 μg/mL Blasticidin
Cell Freezing Medium：FBS+10% DMSO
B-cell maturation antigen (BCMA, CD269, TNFRSF17) is a member of the TNF receptor superfamily. BCMA is expressed in immune organs and mature B lymphocytes. It plays a crucial role in B cell development and autoimmune reactions. Activation of BCMA by its ligands promotes B cell differentiation and proliferation.
The ligands of BCMA, BAFF (B-cell activating factor) and APRIL (proliferation-inducing ligand), are produced by macrophages and dendritic cells. BAFF and APRIL exhibit biological activity as soluble homotrimers.
In multiple myeloma, BCMA is extensively expressed at high levels on malignant plasma cells. BCMA expression increases with progression from normal cells to active multiple myeloma, making it a promising tumor target. Additionally, γ-secretase can cleave surface BCMA to form a soluble form (sBCMA), which acts as a soluble decoy to resist immune cells. Therefore, combining BCMA-targeted antibodies with γ-secretase inhibitors represents a novel treatment approach.
The Hi-Media H_BCMA Reporter Cell Line is a luciferase reporter gene cell line. Upon binding of BAFF or APRIL to the BCMA receptor, downstream signaling pathways are activated, leading to luciferase expression. Blocking antibodies can interfere with this signaling cascade. Luciferase readouts indicate the effectiveness of the signaling pathway activation, making it suitable for evaluating the in vitro effects of BCMA-related drugs.
Cat. No：GM-C25349
Product：H_BCMA Reporter Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+0.75 μg/mL Puromycin+3.5 μg/mL Blasticidin
Cell Freezing Medium：FBS+10% DMSO
B-cell maturation antigen (BCMA, CD269, TNFRSF17) is a member of the TNF receptor superfamily. BCMA is expressed in immune organs and mature B lymphocytes. It plays a crucial role in B cell development and autoimmune reactions. Activation of BCMA by its ligands promotes B cell differentiation and proliferation.
The ligands of BCMA, BAFF (B-cell activating factor) and APRIL (proliferation-inducing ligand), are produced by macrophages and dendritic cells. BAFF and APRIL exhibit biological activity as soluble homotrimers.
In multiple myeloma, BCMA is extensively expressed at high levels on malignant plasma cells. BCMA expression increases with progression from normal cells to active multiple myeloma, making it a promising tumor target. Additionally, γ-secretase can cleave surface BCMA to form a soluble form (sBCMA), which acts as a soluble decoy to resist immune cells. Therefore, combining BCMA-targeted antibodies with γ-secretase inhibitors represents a novel treatment approach.
The Hi-Media H_BCMA Reporter Cell Line is a luciferase reporter gene cell line. Upon binding of BAFF or APRIL to the BCMA receptor, downstream signaling pathways are activated, leading to luciferase expression. Blocking antibodies can interfere with this signaling cascade. Luciferase readouts indicate the effectiveness of the signaling pathway activation, making it suitable for evaluating the in vitro effects of BCMA-related drugs.
